Company Overview and News
Stop missing out on important events!
Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) has 78 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 23,798,585 shares. Largest shareholders include Bvf Inc/il, Vanguard Group Inc, Orbimed Advisors Llc, Renaissance Technologies LLC, Platinum Investment Management Ltd, BlackRock Inc., Deutsche Bank Ag\, Wellington Management Group Llp, Millennium Management Llc, and Baker Brothers Advisors LP. (105-4)
In two January ASCO presentations, BL-8040 showed robust infiltration of anti-tumor T-cells into liver metastases in pancreatic cancer and primes the tumor micro-environment to enhance the effectiveness of immunotherapy agents. (418-13)
Dilution occurred as predicted, although the amount was less than I would have thought in this case. (117-4)
Infinity Pharmaceuticals, Inc. (INFI - Free Report) provided an update on lead pipeline candidate-IPI-549 and also issued financial guidance for 2018. (161-1)
Verastem reported positive top-line data for its lymphoma drug, Duvelisib; the company will submit an NDA in Q1 2018. (110-7)
A de-risked biotech company. Considerable newsflow during the next 12 months. The presentation of P3 data at American Soc. of Hematology, Dec 10, 2017) will likely lead to greater awareness. (177-11)
Investors in Infinity Pharmaceuticals, Inc. (INFI - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Nov 17th 2017 $3.00 Call had some of the highest implied volatility of all equity options today. (97-3)
LONDON, UK / ACCESSWIRE / November 13, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) ("Infinity"), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=INFI. The Company announced on November 10, 2017, Phase-1 clinical and translational data for IPI-549, its oral immuno-oncology development candidate. (84-1)
Readers should pay attention to the safety and tolerability of IPI-549, not response rates in the monotherapy portion of the study. (141-1)
I remind readers of the need to review quarterly results, filings, and conference calls to monitor changes with their stock holdings. (113-0)
I remind readers the importance of constantly reevaluating current holdings in your brokerage accounts and questions to ask ourselves. (128-2)
Infinity Pharmaceuticals, Inc. (INFI - Free Report) reported a loss of 14 cents per share in third-quarter 2017, narrower than the Zacks Consensus Estimate of a loss of 21 cents. The company had reported a loss of 39 cents in the year-ago quarter. (215-1)
Ladies and gentlemen, thank you for standing by. Welcome to the Infinity Pharmaceuticals Conference Call to discuss the Company’s Financial Results for the Third Quarter of 2017. My name is Glenda and I will be your operator for today’s call. At this time, all participants are in a listen-only mode. There will be a question-and-answer session to follow. Please be advised that this call is being recorded at Infinity’s request. (141-0)
I touch on the importance of distinguishing between true high volume institutional selling and momentary temper tantrums thrown by Mr. Market. (98-0)
INFI : Infinity Pharmaceuticals Stock Analysis and Research Report
Infinity Pharmaceuticals is an innovative biopharmaceutical company dedicated to advancing novel medicines for people with cancer. Infinity Pharmaceuticals is focusing its efforts on advancing IPI-549, an orally administered, clinical-stage, immuno-oncology product candidate that selectively inhibits the enzyme phosphoinositide-3-kinase-gamma, or PI3K-gamma.
Preclinical research has demonstrated that PI3K-gamma is highly expressed in tumor-associated macrophages and that blockade of PI3K-gamma signaling by treatment with IPI-549 results in a reprogramming of macrophages in the tumor microenvironment from the M2, or pro-tumor, phenotype to the M1, or anti-tumor, phenotype. This shift increased the number and activity of anti-tumor T cells that can attack the tumor and also increased the production of pro-inflammatory cytokines, which can further stimulate an anti-tumor immune response. Preclinical data from multiple solid tumor models demonstrated that IPI-549 was active as a monothe...